About: CRM1 Inhibitors for Antiviral Therapy

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: CRM1 Inhibitors for Antiviral Therapy Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	CRM1 Inhibitors for Antiviral Therapy
Creator	Ghildyal, Reena Wong, Jack Mathew, Cynthia Qingxiang, Sun Zhou, Haijian
Source	Medline; PMC
abstract	Infectious diseases are a major global concern and despite major advancements in medical research, still cause significant morbidity and mortality. Progress in antiviral therapy is particularly hindered by appearance of mutants capable of overcoming the effects of drugs targeting viral components. Alternatively, development of drugs targeting host proteins essential for completion of viral lifecycle holds potential as a viable strategy for antiviral therapy. Nucleocytoplasmic trafficking pathways in particular are involved in several pathological conditions including cancer and viral infections, where hijacking or alteration of function of key transporter proteins, such as Chromosome Region Maintenance1 (CRM1) is observed. Overexpression of CRM1-mediated nuclear export is evident in several solid and hematological malignancies. Interestingly, CRM1-mediated nuclear export of viral components is crucial in various stages of the viral lifecycle and assembly. This review summarizes the role of CRM1 in cancer and selected viruses. Leptomycin B (LMB) is the prototypical inhibitor of CRM1 potent against various cancer cell lines overexpressing CRM1 and in limiting viral infections at nanomolar concentrations in vitro. However, the irreversible shutdown of nuclear export results in high cytotoxicity and limited efficacy in vivo. This has prompted search for synthetic and natural CRM1 inhibitors that can potentially be developed as broadly active antivirals, some of which are summarized in this review.
has issue date	2017-06-28(xsd:dateTime)
bibo:doi	10.3389/fmicb.2017.01171
bibo:pmid	28702009
has license	cc-by
sha1sum (hex)	5f45e2e283d5ed3b5a842d67bac964bf8a62d851
schema:url	https://doi.org/10.3389/fmicb.2017.01171
resource representing a document's title	CRM1 Inhibitors for Antiviral Therapy
has PubMed Central identifier	PMC5487384
has PubMed identifier	28702009
schema:publication	Front Microbiol
resource representing a document's body	covid:5f45e2e283d5ed3b5a842d67bac964bf8a62d851#body_text
is schema:about of	named entity 'holds' named entity 'inhibitors' named entity 'active' named entity 'LMB' named entity 'However' named entity 'targeting' named entity 'inhibitor' named entity 'VIABLE' named entity 'KEY' named entity 'LEPTOMYCIN B' named entity 'HIGH' named entity 'SEARCH' named entity 'GLOBAL' named entity 'REVIEW' named entity 'FUNCTION' named entity 'CRM1' covid:arg/5f45e2e283d5ed3b5a842d67bac964bf8a62d851 named entity 'function' named entity 'hijacking' named entity 'viral' named entity 'potent' named entity 'viral' named entity 'viral' named entity 'irreversible' named entity 'CRM1' named entity 'transporter proteins' named entity 'nuclear export' named entity 'viral infections' named entity 'Leptomycin' named entity 'development of drugs' named entity 'H1N1' named entity 'exons' named entity 'unspliced' named entity 'unspliced' named entity 'conjugation' named entity 'infection' named entity 'apoptosis' named entity 'Orthomyxoviridae' named entity 'cell cycle arrest' named entity 'tumor' named entity 'toxicity' named entity 'Anti-proliferative' named entity 'response to DNA damage' named entity 'covalently' named entity 'nuclear pore complexes' named entity 'Microbiology' named entity 'HIV-1' named entity 'nuclear export' named entity 'CRM1' named entity 'HTLV-1' named entity 'NES' named entity 'pharmacological properties' named entity 'viruses' named entity 'phosphoprotein' named entity 'protein expression' named entity 'Forkhead' named entity 'unspliced' named entity 'HCT-116' named entity 'protein' named entity 'p21' named entity 'mRNAs' named entity 'protein' named entity 'CRM1' named entity 'CRM1' named entity 'anti-inflammatory' named entity 'apoptosis' named entity 'HTLV-1' named entity 'CRM1' named entity 'influenza virus' named entity 'protein' named entity 'transcription' named entity 'GTPase' named entity 'nucleophilic' named entity 'cytoplasm' named entity 'nuclear transport' named entity 'antiviral' named entity 'CRM1'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software